ФЕБУКСОСТАТ - НОВЫЙ ПРЕПАРАТ В ТЕРАПИИ ПОДАГРЫ

1. <div><p>Okamoto K., Eger B.T., Nishino T. et al. An extremely potent inhibitor of xanthinoxidoreductase. J Bio Chem 2003;278(3):1848-55.</p><p>Fox I.H., Wyngaarden J.B., Kelley W.N. Depletion of erythrocyte phosphoribosylpyrophosphate in man: a newly observed effect of allopurinol. N Engl J Med 1970;283:1177- 82.</p><p>Beardmore T.D., Kelley W.N. Mechanism of allopurinol-mediated inhibition of pyrimidine biosyntesis. J Lab Clin Med 1971;78:696-704.</p><p>Nishida Y., Kamatami N., Tanimoto K., Akaoka I. Inhibition of purine nucleoside phosphorylase activity and of T-cell function with allopurinol-riboside. Agents Actions 1979;9:549-52.</p><p>Fox R.M., Royse-Smith D., O'Sallivan W.J. Orotidinuria induced by allopurinol. Science 1970;168:861-2.</p><p>Zhao L., Takano Y., Horiuchi H. Effect of febuxostat, a novel non-purine, selective inhibitor of xantine oxidase (NP-SIXO), on enzymes in purine and pyrimidine methabolism pathway. Arthr Rheum 2003;48(Suppl. 9):531.</p><p>Bruce S.P. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006;40:2187-94.</p><p>Grabowski B.A., Vernillet L., Khosravan R. et al. Absorbtion, metabolism and excretion of [14C] febuxostat, a novel non-purine selective inhibitor of xantine oxidase, in healthy male subject. Drug Metab Rev 2005;37:111.</p><p>Becker M.A., Kisicki J., Khosravan R. et al. Febuxostat (TMX-67), a novel non-purine selective inhibitor of xantine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004;23:1111-6.</p><p>Khosravan R., Grabowski B.A., Wu J T. et al. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xantine oxidase, in dose escalation study in healthy subjects. Clin Pharmacokinet 2006;45:821-41.</p><p>Komoriya K., Hoshide S., Takeda K. et al. Pharmacokinetics and pharmacodynamics and safety of febuxostat (TMX-67), a non-purine selective inhibitor of xantine oxidase/xantine dehydrogenase (NPSIXO) in patientsbwith gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 2004;23:1119-22.</p><p>Mukoyoshi M., Nishimura S., Hoshide S. et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica 2008;38:496-510.</p><p>Khosravan R., Kukulka M.J., Wu J.T. et al. The effect of age and gender on pharma-cokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2008;48:1014-24.</p><p>Swan S., Khosravan R., Mauer M.D. et al. Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a novel non-purine, selective inhibitor of xanthine oxidase. Arthr Rheum 2003;48(Suppl. 9):529.</p><p>Zhang W., Doherty M., Pascual E. et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1312-24.</p><p>Grabowski B.A., Khosravan R., Wu J.T. et al. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat. Arthr Rheum 2005;52:103-4. 13. 13.</p><p>Grabowski B.A., Khosravan R., Wu J.T. et al. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat. Br J Clin Pharmacol 2010;70(1):57-64.</p><p>Khosravan R., Mayer M.D., Wu J.T. Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state. Arthr Rheum 2005;52(Suppl.)102-3.</p><p>Khosravan R., Wu J.T., Joseph-Ridge N. et al. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol 2006;46:855-66.</p><p>Khosravan R., Kukulka M.J, Wu J.T. et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2008;48:1014-24.</p><p>Becker M.A., Schumacher H.R., Wortmann R.L. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthr Rheum 2005;52(3):916-23.</p><p>Seegmiller J.E. Xantine stone formation. Am J Med 1968;45:780-3.</p><p>Becker M.A., Schumacher H.R., Wortmann R.L. et al Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New Engl J Med 2005;8:2450-61.</p><p>Schumacher H.R., Wortmann R.L., Becker M.A. et al. A phase II, long term open-label safety and efficacy study of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase. Arthr Rheum 2004;50:336.</p><p>Becker M.A., Schumacher H.R., Wortmann R. et al. Magnetic resonance imaging of gouty tophi during treatment with febuxostat, a non-purine selective inhibitor of xanthine oxidase. Arthr Rheum 2004;50:336.</p><p>Becker M.A., Schumacher H.R., Wortmann R. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients. Arthr Rheum 2004;50:336.</p><p>Schumacher H.R., Becker M.A., Wortmann R.L. et al. The FOCUS trial 48-month interim analysis: long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open-label extension study. Ann Rheum Dis 2006;65:93.</p><p>Schumacher H.R., Becker M.A., Wortmann R.L. et al. Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study. Arthr Rheum 2005;52:680.</p><p>Wortmann R.L., Becker M.A.,</p><p>Schumacher H.R. et al. Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trial. ACR/ARHP Annual Scientific Meeting, 2006.</p><p>Becker M.A., Schumacher H.R., Espinoza L. et al. A phase III randomized, controlled, multicenter, double-blind trial comparing efficacy and safety of daily febuxostat and allopurinol in subjects with gout; Presented at: the Meeting of the American College of Rheumatology; October 24-29, 2008; San Francisco, California, abstr L11;57.</p><p>Sanchez-Lozada L.G., Tapia E., Bautista-Garcia P. et al. Effects of febuxostat on metabolic and renal alteration in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2008;294:710-8.</p><p>Nakagawa T., Hu H., Zharikov S. et al. A casual role of uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006;290:625-31.</p><p>EMA (European Medicines Agency) Available at: &lt;http://www.emea.europa.eu/&gt;humandocs/Humans/EPAR/adenuric/adenuric.htm (accessed November 10, 2008). 34.</p><p>NICE (National Institute of Health and Clinical Excellence) 2008a. Available at: &lt;http://www.nice.org.uk/nicemedia/pdf/STA&gt;FebuxostatGoutFAD.pdf</p></div><br />